At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
NE3107drug
Likely dose
NE3107 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias
In Brief
A Phase 2 clinical trial evaluating NE3107 for Alzheimer Disease. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsBioVie Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedFeb 2022
Primary CompletionJul 2022
Study CompletionAug 2022
TodayJul 2026
First PostedFeb 7, 2022
Enrollment StartJan 19, 2022
Primary CompletionJul 20, 2022
Study CompletionAug 20, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.4 years ago
Interventions
NE3107drug
Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)